Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
We randomized 21 patients with low-risk myelodysplastic syndromes (MDS) to receive a single subcutaneous bolus of recombinant erythropoietin (epoietin) +/- granulocyte-colony stimulating factor (G-CSF), or placebo and monitored erythropoietic response over 7 days. In this small study, the reticulocyte response at day 7 was highly predictive of subsequent response to a therapeutic trial of epoietin + G-CSF.
Bowen
David
D
Hyslop
Ann
A
Keenan
Norene
N
Groves
Michael
M
Culligan
Dominic
D
Johnson
Peter
P
Shaw
Ann
A
Geddes
Fiona
F
Evans
Patricia
P
Porter
John
J
Cavill
Ivor
I